🧪🧪 Highest laboratory safety — Novartis relies on Uepaa for its RLT laboratory
Novartis is one of the world's leading pharmaceutical companies headquartered in Basel. The company continuously invests in innovative therapies and cutting-edge research facilities — including in the area of Radioligand Therapy (RLT). In highly specialized laboratories, scientists work every day to develop new treatment options for seriously ill patients.
Safety focus in the RLT laboratory, in accordance with SUVA 44094:
Personal protection is paramount, especially when dealing with radioactive substances and highly sensitive processes. In Novartis RLT laboratories, this means: clear structures, double control — and a safety system that allows no compromises. Immediate notification in an emergency is essential, particularly for activities that are carried out alone. That's where Uepaa comes in.
Direct connection to the internal alarm station:
Novartis has integrated the Uepaa lone worker app in such a way that it is seamlessly connected to the internal alarm chain of the security center. In an emergency, an alarm is automatically forwarded to the appropriate authority without loss of time. This direct connection not only offers the highest response speed, but also meets the strictest safety requirements.
- Automatic accident detection: The app automatically detects motionlessness or falls — without you having to take action yourself.
- Deadman switch: Regular activity checks require manual confirmation — if this is not done, an alarm is triggered immediately.
- Manual alarm: Just press a button to call for immediate help in an emergency.
- Location transfer & connection: The exact position and direct connection to the internal alarm station ensure rapid intervention.
Conclusion — Trust in technology and partnership: With the introduction of the Uepaa lone worker app, Novartis has taken another step towards proactive occupational safety — particularly in one of the company's most sensitive work areas. We would like to thank you for trusting in our solution and look forward to joint development — for more security in tomorrow's research.
